IHS Chemical Week

Regions :: North Asia :: Korea

Lonza Signs Deal with LegoChem Biosciences to Provide Pre-clinical Material of Therapeutic Compound

4:01 AM MST | March 8, 2012 | Deepti Ramesh

Lonza says it has signed an agreement with biotech company LegoChem Biosciences (Daejeon, Korea), for the custom material production of a monoclonal antibody that will be used for in vivo proof of concept studies for their technology platform development. Lonza will produce pre-clinical material using its Light Path discovery services at its applied protein services facility at Cambridge, U.K., under the deal. Lonza’s Light Path discovery services “were specifically designed with the demands of pre-clinical assessment in mind,” says Janet White...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa